Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus drug-eluting stent [DES]. SELUTION DeNovo is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries. Patients are randomized before any vessel preparation to reflect current medical practice and to reduce bias. The objectives of the study are to demonstrate non-inferiority at both one and five years, and superiority for target vessel failure (TVF) at five years. This study is designed to change medical practice, as the majority of de novo coronary lesions are currently treated with a permanent metallic stent. SELUTION SLR consists of an angioplasty balloon coated with MicroRes
Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study thaipr.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thaipr.net Daily Mail and Mail on Sunday newspapers.
This will complement the substantial experience that the company has gained with the SELUTION DeNovo trial in Europe.MedAlliances unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon.
Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study